Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has got marketing approval for NerBloc intramuscular injection 2500 Units in Japan as a treatment for cervical dystonia in adults.
Subscribe to our email newsletter
NerBloc, a botulinum toxin type B neuromuscular-blocking agent has showed improvement in TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) total score from baseline to week four compared with placebo in a double-blind placebo-controlled trial (Study 131).
Eisai has acquired the exclusive rights to develop and market botulinum toxin type B in Japan through an agreement it concluded with US based Elan Pharmaceuticals and Ireland-based Elan Pharma International in September 2000.